These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21231852)

  • 21. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
    Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
    Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian stimulation in women with high and normal body mass index: GnRH agonist versus GnRH antagonist.
    Marci R; Lisi F; Soave I; Lo Monte G; Patella A; Caserta D; Moscarini M
    Gynecol Endocrinol; 2012 Oct; 28(10):792-5. PubMed ID: 22397576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of growth hormone on IVF/ICSI outcomes and endometrial receptivity of patients undergoing GnRH antagonist protocol with fresh embryo transfer: a pilot study.
    Chu Y; Wang L; Xie J; Yang S; Liu S; Hu D; Yue J
    Front Endocrinol (Lausanne); 2023; 14():1225121. PubMed ID: 37727454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro fertilization stimulation protocol for normal responder patients.
    Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
    Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting clinical pregnancy in controlled ovarian hyperstimulation with GnRH-a long protocol: a retrospective cross-sectional study.
    Fan Y; Sun YF; Xu YM; Cao ZY; Luo ZY; Sun Y; Zhao ZM; Hao GM; Gao BL
    J Obstet Gynaecol; 2022 Aug; 42(6):2486-2491. PubMed ID: 35678767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial.
    Haydardedeoglu B; Kilicdag EB; Parlakgumus AH; Zeyneloglu HB
    Arch Gynecol Obstet; 2012 Sep; 286(3):763-9. PubMed ID: 22569710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled ovarian hyperstimulation for in vitro fertilization alters endometrial receptivity in humans: protocol effects.
    Haouzi D; Assou S; Dechanet C; Anahory T; Dechaud H; De Vos J; Hamamah S
    Biol Reprod; 2010 Apr; 82(4):679-86. PubMed ID: 20042535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
    Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
    Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
    Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles.
    Kinay T; Tasci Y; Dilbaz S; Cinar O; Demir B; Haberal A
    Gynecol Endocrinol; 2010 Nov; 26(11):833-7. PubMed ID: 20504095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial but not Ovarian Response is Associated With Clinical Outcomes and can be Improved by Prolonged Pituitary Downregulation in Patients With Thin and Medium Endometrium.
    Song J; Sun X; Qian K
    Reprod Sci; 2019 Nov; 26(11):1409-1416. PubMed ID: 30501453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.